Overbeck Franz Camille (1837-1905)

(Résumé de l'ouvrage) Cette publication s'inscrit dans une perspective sociale et culturelle : articuler des données historiques par rapport à leurs significations, leurs résonances imaginaires, leurs effets sociaux, leur statut de références symboliques. Elle offre ainsi au lecteur un panorama du protestantisme d'aujourd'hui, avec ses forces et ses faiblesses. Cette nouvelle édition (coédition avec Labor et Fides) est entièrement revue, corrigée et augmentée. Elle est constituée de 48 "grands dossiers" et d'environ 1400 "petites rubriques" consacrés soit à des personnalités soit à des notions significatives du "fait protestant". Cette encyclopédie s'inscrit dans les débats contemporains où le rapport au religieux s'impose comme objet de réflexion au coeur d'une Europe construite dans une matrice chrétienne.

Long-term follow-up of follicular lymphoma (FL) patients receiving single agent rituximab at two different schedules in trial SAKK 35/98

Background: In FL, Rituximab as a single agent delivered in the standard schedule (4 times weekly) may induce a response rate of 50−70% with an event-free survival (EFS) of 1−3 years according to patients' characteristics. Prolonged Rituximab exposure seems to improve EFS at least in responding patients and to increase the rate of longterm responders. Here we report long-term results of a clinical trial comparing single agent Rituximab delivered in the standard schedule versus prolonged exposure, with focus on the proportion of long-term responders and their characteristics. Material and Methods: Between 1998 and 2002, chemotherapy na¨ıve (n = 64) or pre-treated (n = 138) FL patients received Rituximab in the standard schedule. Those responding or with stable disease were randomized to no further treatment (observation, n = 78) or 4 additional doses of Rituximab given at 2-month intervals (prolonged exposure, n = 73). EFS was calculated from the first dose of standard schedule until progression, relapse, second tumor or death. Results: At a median follow up of 9.4 years and with all living patients having been followed for at least 5 years, the median EFS is 13 months for the observation and 24 months for the prolonged exposure arm (p = 0.0007). In the observation arm 13% had no event at 5-years and only 4% at 8 years, while in the prolonged exposure arm it was 27% at 5 years and remained 21% at 8 years. The only significant prognostic factor for EFS in a multivariate Cox regression was the prolonged Rituximab schedule (hazard ratio 0.58, CI 0.39−0.86, p = 0.007), whereas being chemotherapy na¨ıve, presenting with stage